InflaRx: Cost Discipline and Strategic Refocus on Izicopan Underpin Buy Rating

H.C. Wainwright analyst Matthew Keller reiterated a Buy rating on InflaRx today and set a price target of $6.00.

Matthew Keller has given his Buy rating due to a combination of factors that, in his view, materially strengthen InflaRx’s strategic and financial position. He points to the company’s decision to cut costs and streamline operations—particularly by scaling back spending on vilobelimab—as a disciplined way to free up capital for higher‑priority assets. These changes are expected to meaningfully extend InflaRx’s cash runway, providing more time and resources for value‑creating clinical milestones without immediate financing pressure. Keller also notes that InflaRx is not abandoning vilobelimab entirely, as it continues to support the BARDA‑backed ARDS trial and seek partnerships, preserving upside potential from that program.

At the same time, Keller emphasizes that the company is now squarely focused on advancing izicopan in immunological and inflammatory diseases, which he views as the primary driver of long‑term value. Recent clinical results for izicopan in hidradenitis suppurativa and chronic spontaneous urticaria were characterized as compelling and support the ongoing development of the drug. The company’s plans to initiate a Phase 2b trial in hidradenitis suppurativa, engage with the FDA on subsequent trial design, and conduct a pharmacokinetic bridging study in China highlight a clear, forward‑looking clinical roadmap. Keller further expects upcoming regulatory feedback and indication decisions to act as additional catalysts, reinforcing his positive outlook and supporting his Buy recommendation on InflaRx shares.

According to TipRanks, Keller is an analyst with an average return of -27.1% and a 21.43% success rate. Keller covers the Healthcare sector, focusing on stocks such as Gyre Therapeutics, InflaRx, and Galectin Therapeutics.